论文部分内容阅读
目的:观察重组人白细胞介素-2(rhIL-2)瘤内注射和阿霉素白蛋白磁微球(ADM-MAM)联合外磁场联合治疗H22荷瘤小鼠 的协同作用,并探讨其抗肿瘤作用机制。方法:以荷瘤小鼠的瘤重为指标,观察药物的抗肿瘤活性。以乳酸脱氢酶释放法测NK细胞的杀伤活性。以MTT比色法测淋巴细胞的转化率。以流式细胞术检测肿瘤细胞的凋亡及p53、Fas和FasL的表达。用RT-PCR法测定IL-2及IL-12的表达。探讨抗肿瘤机制。结果:ADM-MAM靶向治疗与rhIL-2联用,可显著减小荷瘤小鼠的瘤重;提高NK细胞的杀伤活性和脾脏淋巴细胞的转化率;减小肿瘤细胞的增殖指数,上调肿瘤细胞p53、Fas和FasL的表达,以及增加脾脏淋巴细胞上IL-2及IL-12的表达。结论:ADM-MAM联合外磁场,具有显著增强抑瘤的作用。rhIL-2能增强ADM-MAM靶向治疗的抗肿瘤作用,其抗肿瘤协同作用主要是通过促进T细胞增殖,刺激NK细胞增长等提高机体的免疫功能而实现的。
OBJECTIVE: To observe the synergistic effect of recombinant human interleukin-2 (rhIL-2) intratumoral injection and adriamycin albumin magnetic microspheres (ADM-MAM) in combination with external magnetic field in H22 tumor-bearing mice and to explore its anti-tumor effect Tumor mechanism. Methods: The tumor weight of tumor-bearing mice as an indicator to observe the anti-tumor activity of the drug. Killing activity of NK cells was measured by lactate dehydrogenase release assay. The conversion of lymphocytes was measured by MTT colorimetry. The apoptosis of tumor cells and the expression of p53, Fas and FasL were detected by flow cytometry. The expression of IL-2 and IL-12 was measured by RT-PCR. Explore anti-tumor mechanisms. Results: ADM-MAM combined with rhIL-2 could significantly reduce the tumor weight of tumor-bearing mice, increase the killing activity of NK cells and the conversion rate of spleen lymphocytes, and decrease the proliferation index of tumor cells The expression of p53, Fas and FasL in tumor cells and the expression of IL-2 and IL-12 in spleen lymphocytes were increased. Conclusion: ADM-MAM combined with external magnetic field, has significantly enhanced the role of anti-tumor. The anti-tumor effect of rhIL-2 can enhance the targeted therapy of ADM-MAM. The anti-tumor synergetic effect of rhIL-2 is mainly through the promotion of T cell proliferation, stimulation of NK cell growth and so on to improve the body’s immune function.